Background
Effector functions of anti-HIV bnAbs may contribute to viral suppression as well as reservoir reduction via recruitment of immune cells and complement fixation to destroy HIV-infected cells. The contribution of native effector functions to the antiviral activity of N6LS has previously been explored (Wang, et al. PNAS. 2020. 117(30):18002-18009) and N6LS is currently in clinical trials (NCT05996471). We wished to determine if the effector functions of N6LS could be further enhanced through modification of the Fc region.
Methods
Sixty-one variants of N6 bnAb were expressed and purified. For effector function enhancement, combinations of amino acid substitutions in the Fc region (including S239D, I332E, G236A, A330L in varied combinations; H268F/S324T; F243L/R292P/Y300L/V305I/P396L) were examined, as were alterations to the N297 glycan. For half-life extension, the M428L/N434S (LS) and L309D/Q311H/N434S (DHS) substitution sets were tested, as were alterations to the surface charge distribution of the light chain (R18E/R42E/K45E). These bnAbs were assessed for developability properties, antiviral activity, effector functions, immunogenicity risk, and other drug-like characteristics.
Results
The R18E/R42E/K45E light chain substitutions generally resulted in poor expression and were not assessed further. The remaining variants all showed similar affinity for gp120 and direct antiviral activity in a pseudovirus assay. No functional difference between the LS and DHS half-life extension substitutions was observed. The S239D/I332E substitutions reduced thermal stability, which could be restored by the addition of T250V/A287F. SPR-based FcGR binding assessment allowed for the binning of variants by FcGR affinity profile; all showed enhanced affinity for the FcGR3a (7- to over 200-fold), which mediates ADCC activity of NK cells, but varied in their affinities for other FcGRs. ADCC assays indicated improved NK-mediated killing of gp160-expressing cells that roughly correlated with FcGR3a affinity improvement. The most potent variants showed both an increase in maximal cell killing capacity as well as ~100-fold greater potency relative to unmodified N6 bnAb.
Conclusions
Multiple variants of the N6 bnAb displayed suitable developability properties and varying degrees of effector function enhancement in vitro. Four variants were identified for continued in vitro and in vivo assessment, including initiation of stable cell lines for potential manufacture.